Bicarbonate-defined metabolic acidosis among adults receiving intravenous methocarbamol: a historical cohort study
Pharmaceutics and Pharmacology · 14.11.2026
DOI: 10.1093/pp/rqag010 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pharmaceutics and Pharmacology, online erschienen am 14.11.2026. Verfasst von Coleton Waggoner und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Intravenous (IV) methocarbamol contains the diluent polyethylene glycol (PEG), which carries a risk for metabolic acidosis. Previous reports of metabolic acidosis among patients treated with IV methocarbamol vary widely and encompass various sources, including historical case series and spontaneous adverse event reporting. The purpose of this project was to characterise the proportion of monitored IV methocarbamol orders meeting bicarbonate-defined metabolic acidosis among hospitalised adults.
Methods
This was a single-centre historical cohort study of adults 18 years and older who received at least 3 consecutive doses of IV methocarbamol. Metabolic acidosis was defined by the 2024 Kidney Disease: Improving Global Outcomes definition as a serum bicarbonate level less than 18 mmol/L (i.e., bicarbonate-defined metabolic acidosis). Key Findings Six of 44 monitored IV methocarbamol orders met the bicarbonate-defined metabolic acidosis criterion during exposure (13.6%, 95% CI 6.4% to 26.7%); of these, four were incident cases that developed during therapy and two were prevalent at baseline and persisted during therapy. Among 42 orders at risk at baseline, the incident proportion was 4/42 (9.5%, 95% CI 3.8% to 22.1%); a patient-level analysis yielded 5/43 (11.6%, 95% CI 5.1% to 24.5%).
Conclusions
The proportion of monitored IV methocarbamol orders meeting the bicarbonate-defined metabolic acidosis criterion was 13.6% (6/44), with an incident proportion of 9.5% (4/42) among orders at risk at baseline. Given the descriptive, single-centre design, these findings require confirmation using additional diagnostic criteria and controlled study designs.
Zitieren
APA
Waggoner, C., Ngo, J., Chan, E., & Boylan, P. M. (2026). Bicarbonate-defined metabolic acidosis among adults receiving intravenous methocarbamol: a historical cohort study. Pharmaceutics and Pharmacology. https://doi.org/10.1093/pp/rqag010
Vancouver
Waggoner C, Ngo J, Chan E, Boylan PM. Bicarbonate-defined metabolic acidosis among adults receiving intravenous methocarbamol: a historical cohort study. Pharmaceutics and Pharmacology. 2026. doi:10.1093/pp/rqag010
BibTeX
@article{Waggoner2026,
author = {Waggoner, Coleton and Ngo, James and Chan, Emilie and Boylan, Paul M},
title = {Bicarbonate-defined metabolic acidosis among adults receiving intravenous methocarbamol: a historical cohort study},
journal = {Pharmaceutics and Pharmacology},
year = {2026},
doi = {10.1093/pp/rqag010}
}
EUVIMED